Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir

Seth M. Pransky, James Albright, Anthony E. Magit

Research output: Contribution to journalArticlepeer-review

77 Scopus citations


Objective: Cidofovir is an acyclic nucleotide phosphonate antiviral medication that has been used intralesionally for the treatment of severe respiratory papillomatosis (RRP) in pediatric patients. The long-term efficacy of this medication was assessed in 11 children with severe RRP who previously required operative debulking every 2 to 6 weeks to maintain airway patency. Study Design: Clinical case series. Results: Ten of these children have completed therapy. Five are disease free over a mean follow-up period of 51.6 months. Five other patients with active RRP decreased their mean severity scores from 17.8 (range 11-26) to 4.0 (range 2-6) and no longer require cidofovir. One patient continues to receive cidofovir for recurrent disease after an initial favorable response. Throughout the 6-year observational period, no patients demonstrated any adverse effects, laboratory abnormalities, or evidence of carcinogenesis. Conclusion: Intralesional cidofovir is a useful adjunct for managing children with tenuous airways caused by previously uncontrolled papilloma.

Original languageEnglish (US)
Pages (from-to)1583-1587
Number of pages5
Issue number9
StatePublished - Sep 1 2003


  • Cidofovir
  • Pediatric airway
  • Recurrent respiratory papillomatosis

ASJC Scopus subject areas

  • Otorhinolaryngology


Dive into the research topics of 'Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir'. Together they form a unique fingerprint.

Cite this